Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals

• Published in: Birth defects research. Part B. Developmental and reproductive toxicology Vol. 86; no. 3; pp. 176 - 203
• Main Authors: Martin, Pauline L., Breslin, William, Rocca, Meredith, Wright, David, Cavagnaro, Joy
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-06-2009
• Subjects: Algorithms; Animals; biopharmaceuticals; Biopharmaceutics - methods; biotherapeutics; Drug Evaluation, Preclinical - methods; Drug-Related Side Effects and Adverse Reactions - diagnosis; embryo/fetal development; Embryonic Development - drug effects; Female; Pan troglodytes; Placenta - drug effects; Placenta - metabolism; Pregnancy; Primates; reproduction; Reproduction - drug effects; Risk Assessment; Toxicity Tests - methods
• ISSN: 1542-9733; 1542-9741
• DOI: 10.1002/bdrb.20197

This report discusses the principles of developmental and reproductive toxicity (DART) testing for biopharmaceuticals. Biopharmaceuticals are large‐molecular‐weight proteins or peptides produced by modern biotechnology techniques incorporating genetic engineering and hybridoma technologies. The principles of DART testing for biopharmaceuticals are similar to those for small‐molecule pharmaceuticals and in general follow the regulatory guidance outlined in International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) document S5(R2). However, because many biopharmaceuticals are species‐specific, alternate approaches may be needed to evaluate DART potential as outlined in ICH S6. For molecules that show species‐specific cross‐reactivity restricted to non‐human primates (NHP), some aspects of DART may require NHP testing. For biopharmaceuticals that are uniquely specific and only active on intended human targets or human and chimpanzee targets, surrogate molecules that cross‐react with the more traditional rodent species may need to be developed and used for DART testing. Alternatively, genetically modified transgenic animals may also need to be considered. Surrogate molecules and transgenic animals may also be considered for DART testing even if the biopharmaceutical is active in NHPs in order to reduce the use of NHPs. Because of the unique properties of biopharmaceuticals, a case‐by‐case approach is needed for DART and general toxicity evaluation, which requires consideration of specific product attributes including biochemical and biophysical characteristics, pharmacological activity, and intended clinical indication. Birth Defects Res (Part B), 33:176–203, 2009. © 2009 Wiley‐Liss, Inc.